Study to Evaluate the Efficacy of FOLFOX + Panitumumab Followed by FOLFIRI + Bevacizumab (Sequence 1) Versus FOLFOX + Bevacizumab Followed by FOLFIRI + Panitumumab (Sequence 2) in Untreated Patients With Wild-type RAS Metastatic, Primary Left-sided, Unresectable Colorectal Cancer
Clinical trial NCT03635021 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03635021
- Sponsor
- Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2018-10-15
- Primary completion
- 2025-06-28
- Enrollment
- 419
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.